IDH1 and glioblastoma: Because IDH mutation status was unavailable in 51 (20%) and 41 (19.7%) patients in the OS and PFS TCIA/TCGA-GBM datasets, respectively, its surrogate G-CIMP status (unavailable in 5 (2%) and 2 (1%) patients, respectively) was used to adjust the effect of VSVZ contact status.